Abstract 159P
Background
The impact of time on the efficacy of advanced distal gastric cancer (ADGC) remains unclear. At 3 years postoperatively, the efficacy of oncologic surgery for ADGC needs to be confirmed.
Methods
A total of 1256 patients with ADGC at two teaching institutions in China from April 2007 to December 2014 were enrolled. The general data of the two groups were matched using propensity scores. Restricted mean survival time (RMST) was used to compare survival.
Results
After matching, 461 patients each in the open distal gastrectomy (ODG) and laparoscopic distal gastrectomy (LDG) groups were analyzed. The 3- and 5-year overall survival (OS) and disease-free survival in ODG group were comparable to those in LDG group. RMST-stratified analysis showed that the 3-year RMST of ODG group was similar to that of LDG group (-1.38 years, P=0.163) in cT4a patients, whereas the 5-year RMST had significant differences between groups (-8.36 years, P=0.005). In further stratified analysis, when patients with cT4a and tumor was >5 cm, the 3-year RMST of ODG group was similar to that of LDG group (0.98 year, P=0.480); however, the 5-year RMST was significantly longer in ODG group (4.67 years, P=0.042). Multivariate regression analysis showed that ODG is a protective factor for 5-year OS in patients with cT4a and tumors >5 cm.
Conclusions
Beyond 3 years, ODG can improve the survival of patients with serous infiltration and tumors >5 cm by reducing the risk of recurrence. The present findings can serve as a reference for the preoperative selection of GC surgery options and the setting of follow-up time for clinical studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
349P - Proteinuria in patients treated with ramcirumab increases the risk of renal dysfunction
Presenter: Kenta Hayashino
Session: e-Poster Display Session
350P - Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience
Presenter: Azim Khan
Session: e-Poster Display Session
351P - Valvular heart diseases in patients treated for breast cancer
Presenter: Ekaterina Kushnareva
Session: e-Poster Display Session
352P - Reproductive system disorders following chemotherapy in patients with breast cancer in Yogyakarta, Indonesia
Presenter: Irfan Haris
Session: e-Poster Display Session
353P - Survey for geriatric assessment in practising oncologists in India
Presenter: Vikas Talreja
Session: e-Poster Display Session
354P - Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM)
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
355P - Impact of comorbidities and rurality on treatment commencement, completion and outcomes, and health related quality of life, for geriatric oncology patients: Preliminary findings from a regional Australian study
Presenter: Mathew George
Session: e-Poster Display Session
357P - Comparison between immunotherapy and chemotherapy as neoadjuvant setting in resectable non-small cell lung cancer: A systematic review and meta-analysis of prospective trials
Presenter: Chao Zhang
Session: e-Poster Display Session
358P - Adjuvant tyrosine kinase inhibitors in non-squamous non-small cell lung cancer with EGFR driver mutations: An updated meta-analysis of randomized trials
Presenter: Joanmarie Balolong-Garcia
Session: e-Poster Display Session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session